HK1214152A1 - 用於肌萎縮性側索硬化的治療劑 - Google Patents

用於肌萎縮性側索硬化的治療劑

Info

Publication number: HK1214152A1
Authority: HK; Hong Kong
Prior art keywords: therapeutic agent; lateral sclerosis; amyotrophic lateral; amyotrophic; sclerosis
Prior art date: 2012-10-24

Application number

HK16102170.0A

Other languages

English (en)

Inventor

Tsuyoshi Matsuo

Norihito Murayama

Mayumi Furuya

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-24

Filing date

2016-02-25

Publication date

2016-07-22

2016-02-25 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2016-07-22 Publication of HK1214152A1 publication Critical patent/HK1214152A1/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Marine Sciences & Fisheries (AREA)
Cell Biology (AREA)

HK16102170.0A 2012-10-24 2016-02-25 用於肌萎縮性側索硬化的治療劑 HK1214152A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2012234300		2012-10-24
PCT/JP2013/078743 WO2014065341A1 (ja)	2012-10-24	2013-10-23	筋萎縮性側索硬化症治療剤

Publications (1)

Publication Number	Publication Date
HK1214152A1 true HK1214152A1 (zh)	2016-07-22

Family

ID=50544716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK16102170.0A HK1214152A1 (zh)	2012-10-24	2016-02-25	用於肌萎縮性側索硬化的治療劑

Country Status (12)

Country	Link
US (1)	US20150265680A1 (zh)
EP (1)	EP2913063B1 (zh)
JP (1)	JP6262661B2 (zh)
KR (3)	KR102499918B1 (zh)
CN (2)	CN104853778A (zh)
AU (1)	AU2013335678B9 (zh)
BR (1)	BR112015009107A2 (zh)
CA (1)	CA2889499C (zh)
HK (1)	HK1214152A1 (zh)
IN (1)	IN2015DN04172A (zh)
RU (1)	RU2655811C2 (zh)
WO (1)	WO2014065341A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10092621B2 (en)	2014-11-12	2018-10-09	Lyric Pharmaceuticals Inc.	Treatment of enteral feeding intolerance
WO2017083882A1 (en) *	2015-11-11	2017-05-18	Lyric Pharmaceuticals Inc.	Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
CN113365640A (zh) *	2018-12-06	2021-09-07	比奥根Ma公司	引导肌萎缩侧索硬化症的治疗性干预的神经丝蛋白
US11969416B1 (en)	2022-11-03	2024-04-30	Lumos Pharma, Inc.	Compactable oral formulations of ibutamoren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5668254A (en)	1990-05-11	1997-09-16	Romano Deghenghi	D-2-alkyl-tryptophan and peptides containing same
US5663146A (en)	1991-08-22	1997-09-02	Administrators Of The Tulane Educational Fund	Polypeptide analogues having growth hormone releasing activity
US5536716A (en)	1992-12-11	1996-07-16	Merck & Co., Inc.	Spiro piperidines and homologs which promote release of growth hormone
TW432073B (en)	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
EP1105376B1 (en)	1998-08-20	2005-02-09	Sumitomo Pharmaceuticals Company, Limited	Oxindole derivatives as growth hormone releasers
BRPI0012688B8 (pt)	1999-07-23	2021-05-25	Kangawa Kenji	método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas
UA73530C2 (uk)	1999-11-10	2005-08-15	Ново Нордіск А/С	Сполука з властивостями вивільнювати гормон росту
EP1258250B1 (en) *	1999-12-28	2005-09-14	Kaken Pharmaceutical Co., Ltd.	Nerve protective drugs
DK1289951T3 (da)	2000-06-13	2005-12-19	Zentaris Gmbh	Væksthormon sekretionsfremmere
WO2003084983A1 (fr)	2002-04-11	2003-10-16	Daiichi Suntory Pharma Co., Ltd.	Procede de production d'un peptide modifie
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja)	2004-01-30	2005-09-08	Kaken Pharmaceut Co Ltd	神経突起伸展剤
WO2006079077A2 (en) *	2005-01-20	2006-07-27	Acadia Pharmaceuticals Inc.	Use of diltiazem or analogs thereof as modulators of ghrelin receptor
US7829589B2 (en)	2005-06-10	2010-11-09	Elixir Pharmaceuticals, Inc.	Sulfonamide compounds and uses thereof
WO2007046347A1 (ja) *	2005-10-18	2007-04-26	Ono Pharmaceutical Co., Ltd.	筋萎縮性側索硬化症患者の運動神経保護用医薬
WO2007146046A2 (en)	2006-06-07	2007-12-21	Genzyme Corporation	Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
JP2008127377A (ja)	2006-11-24	2008-06-05	Jichi Medical Univ	Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko)	2008-03-27	2010-03-10	주식회사 하이닉스반도체	반도체 소자의 수직형 트랜지스터 및 그 형성방법
KR101273187B1 (ko) *	2008-04-03	2013-06-17	에프. 호프만-라 로슈 아게	신경근 장애의 치료를 위한 폴리(에틸렌글리콜)(ｐｅｇ)-부착된 ｉｇｆ-ｉ 변이체의 용도

2013
- 2013-10-23 CN CN201380066625.1A patent/CN104853778A/zh active Pending
- 2013-10-23 BR BR112015009107A patent/BR112015009107A2/pt not_active Application Discontinuation
- 2013-10-23 AU AU2013335678A patent/AU2013335678B9/en active Active
- 2013-10-23 CA CA2889499A patent/CA2889499C/en active Active
- 2013-10-23 WO PCT/JP2013/078743 patent/WO2014065341A1/ja active Application Filing
- 2013-10-23 EP EP13848825.9A patent/EP2913063B1/en active Active
- 2013-10-23 RU RU2015119472A patent/RU2655811C2/ru active
- 2013-10-23 KR KR1020227012378A patent/KR102499918B1/ko active Active
- 2013-10-23 KR KR1020207026038A patent/KR20200108494A/ko not_active Withdrawn
- 2013-10-23 IN IN4172DEN2015 patent/IN2015DN04172A/en unknown
- 2013-10-23 CN CN201910808882.7A patent/CN110354265A/zh active Pending
- 2013-10-23 US US14/437,459 patent/US20150265680A1/en not_active Abandoned
- 2013-10-23 JP JP2014543332A patent/JP6262661B2/ja active Active
- 2013-10-23 KR KR1020157010085A patent/KR20150070180A/ko not_active Ceased
2016
- 2016-02-25 HK HK16102170.0A patent/HK1214152A1/zh unknown

Also Published As

Publication number	Publication date
JPWO2014065341A1 (ja)	2016-09-08
BR112015009107A2 (pt)	2017-11-14
CN104853778A (zh)	2015-08-19
EP2913063A1 (en)	2015-09-02
JP6262661B2 (ja)	2018-01-17
US20150265680A1 (en)	2015-09-24
CA2889499C (en)	2019-09-10
RU2655811C2 (ru)	2018-05-29
CA2889499A1 (en)	2014-05-01
EP2913063B1 (en)	2019-09-11
AU2013335678B2 (en)	2017-10-26
KR20150070180A (ko)	2015-06-24
KR20200108494A (ko)	2020-09-18
IN2015DN04172A (zh)	2015-10-16
CN110354265A (zh)	2019-10-22
KR102499918B1 (ko)	2023-02-14
RU2015119472A (ru)	2016-12-20
AU2013335678B9 (en)	2024-12-12
WO2014065341A1 (ja)	2014-05-01
EP2913063A4 (en)	2016-07-20
AU2013335678A1 (en)	2015-05-21
KR20220051418A (ko)	2022-04-26

Publication	Publication Date	Title
HK1203963A1 (zh)	2015-11-06	新型治療藥物
GB201212513D0 (en)	2012-08-29	Therapeutic agents
HK1208628A1 (zh)	2016-03-11	用於肝臟疾病的預防劑或治療劑
HK1206620A1 (zh)	2016-01-15	血脂異常症治療劑
HK1214269A1 (zh)	2016-07-22	肌萎縮側索硬化症治療
HK1201209A1 (zh)	2015-08-28	糖尿病的治療藥
GB201217704D0 (en)	2012-11-14	Therapeutic agents
HK1206976A1 (zh)	2016-01-22	外用劑組合物
PL2723330T3 (pl)	2015-12-31	Lek kombinowany zawierający środek naczynioskurczowy
GB2525835B (en)	2017-06-07	Pharmaceutical agent
HK1219224A1 (zh)	2017-03-31	角結膜病症的治療劑
HK1214152A1 (zh)	2016-07-22	用於肌萎縮性側索硬化的治療劑
GB201420971D0 (en)	2015-01-07	Therapeutic composition
HK1207311A1 (zh)	2016-01-29	變態反應改善劑
EP2919816A4 (en)	2016-05-25	COMBINATION TREATMENT FOR AMYOTROPHE LATERAL SCLEROSIS (ALS)
EP2814479A4 (en)	2015-07-01	METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS
HK1203406A1 (zh)	2015-10-30	用於治療肌萎縮側索硬化症的新組合物
SMT201700373T1 (it)	2017-09-07	Nuove composizioni per il trattamento della sclerosi laterale amiotrofica
ZA201405764B (en)	2017-09-27	Novel therapeutic agents
GB201223021D0 (en)	2013-02-06	Therapeutic agents
IL236873A0 (en)	2015-03-31	therapeutic compounds
GB201212512D0 (en)	2012-08-29	Therapeutic agents
GB201210233D0 (en)	2012-07-25	Therapeutic agents
GB201214985D0 (en)	2012-10-03	Modified therapeutic agents
GB201213712D0 (en)	2012-09-12	Modified therapeutic agents